We identified 276 patients with primary retroperitoneal WDLS and 353 patients with primary retroperitoneal DDLS who underwent resection between July 1982 and July 2021 at our institution. WDLS ...
High TMB and TAM density may predict positive ICI response in DDLPS patients, as shown in a case with pembrolizumab achieving pCR. The patient, initially treated with doxorubicin, pazopanib, and ...
Building on her discovery of the GLP-1 signaling pathway's role in sarcoma biology, Erica Pimenta, MD, PhD, of the ...
nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program. Genetic abnormalities and aberrant ...
This biological process, where mature, specialized cells lose their distinct characteristics and revert to a more primitive, ...
MD Anderson-led Phase II trial suggests neoadjuvant immunotherapy is safe and may be an effective option for patients with soft-tissue sarcomas After treatment with a combination of immunotherapy and ...
Please provide your email address to receive an email when new articles are posted on . Milademetan failed to significantly extend PFS among patients with dedifferentiated liposarcoma, according to ...
In part 3 of an interview, MD Anderson’s Ravin Ratan, MD, MEd, discusses neoadjuvant immune checkpoint blockade for 2 specific types of soft tissue sarcomas. Liposarcomas originate in fat cells and ...
Rain Oncology is a late-stage oncology company. Their lead product, milademetan, is an oral inhibitor of the MDM2-p53. In the past, MDM2 inhibitors have been associated with severe hematologic events.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results